NASDAQ:MGTX - Nasdaq - KYG596651029 - Common Stock - Currency: USD
6.48
+0.15 (+2.37%)
The current stock price of MGTX is 6.48 USD. In the past month the price increased by 17.82%. In the past year, price increased by 47.27%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.06 | 327.65B | ||
AMGN | AMGEN INC | 13.95 | 155.74B | ||
GILD | GILEAD SCIENCES INC | 13.95 | 134.34B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.15B | ||
REGN | REGENERON PHARMACEUTICALS | 11.59 | 55.45B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.72B | ||
ARGX | ARGENX SE - ADR | 93.55 | 32.85B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.47 | 27.35B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.10B | ||
NTRA | NATERA INC | N/A | 23.35B | ||
BIIB | BIOGEN INC | 8 | 18.54B | ||
INSM | INSMED INC | N/A | 18.12B |
MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 381 full-time employees. The company went IPO on 2018-06-08. The firm is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
MEIRAGTX HOLDINGS PLC
450 East 29Th Street, 14Th Floor
New York City NEW YORK 10016 US
CEO: Alexandria Forbes
Employees: 378
Phone: 16468607985
The current stock price of MGTX is 6.48 USD. The price increased by 2.37% in the last trading session.
The exchange symbol of MEIRAGTX HOLDINGS PLC is MGTX and it is listed on the Nasdaq exchange.
MGTX stock is listed on the Nasdaq exchange.
11 analysts have analysed MGTX and the average price target is 23.46 USD. This implies a price increase of 262.04% is expected in the next year compared to the current price of 6.48. Check the MEIRAGTX HOLDINGS PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MEIRAGTX HOLDINGS PLC (MGTX) has a market capitalization of 520.80M USD. This makes MGTX a Small Cap stock.
MEIRAGTX HOLDINGS PLC (MGTX) currently has 378 employees.
MEIRAGTX HOLDINGS PLC (MGTX) has a support level at 6.47 and a resistance level at 6.64. Check the full technical report for a detailed analysis of MGTX support and resistance levels.
The Revenue of MEIRAGTX HOLDINGS PLC (MGTX) is expected to grow by 1032.69% in the next year. Check the estimates tab for more information on the MGTX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MGTX does not pay a dividend.
MEIRAGTX HOLDINGS PLC (MGTX) will report earnings on 2025-08-11, before the market open.
MEIRAGTX HOLDINGS PLC (MGTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.32).
The outstanding short interest for MEIRAGTX HOLDINGS PLC (MGTX) is 6.5% of its float. Check the ownership tab for more information on the MGTX short interest.
ChartMill assigns a technical rating of 9 / 10 to MGTX. When comparing the yearly performance of all stocks, MGTX is one of the better performing stocks in the market, outperforming 82.93% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to MGTX. MGTX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months MGTX reported a non-GAAP Earnings per Share(EPS) of -2.32. The EPS decreased by -15.42% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -74.7% | ||
ROE | -505.54% | ||
Debt/Equity | 2.22 |
ChartMill assigns a Buy % Consensus number of 84% to MGTX. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 101.15% and a revenue growth 1032.69% for MGTX